Adam S Grossman, CEO of ADMA Biologics, Inc., bought 13,400 shares of ADMA Biologics, Inc. (Stock Symbol: ADMA) at $7.50 per share for a total amount of $100.5 thousand on May 15, 2014.
ADMA Biologics, Inc. is headquartered in Ramsey, New Jersey.
On 04/03/2014, ADMA Biologics, Inc., a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced that its abstract titled “POLYCLONAL HUMAN INTRAVENOUS IMMUNE GLOBULIN (IGIV) WITH HIGH-LEVELS OF RSV NEUTRALIZING ANTIBODIES: A SUMMARY OF ANIMAL AND HUMAN STUDIES” was accepted for a poster presentation during the 2014 Clinical Immunology Society (CIS) meeting.
On 05/12/2014, ADMA Biologics, Inc. announced its latest quarterly results. ADMA Biologics continued to make clinical and financial progress during the first quarter. Our ongoing pivotal Phase III study has advanced as expected and is on schedule to report preliminary data later this year. During the first quarter, we added to our capital resources with approximately $5 million of new funding, strengthening our cash position through the refinancing of our notes with Hercules Technology Growth Capital (HTGC). We have an additional tranche of $5 million available at our option upon achieving a future milestone.
According to Capital IQ, ADMA Biologics, Inc. has a market cap of $69.68 million, an enterprise value of $69.69 million, and trailing 12 month revenues of $3.84 million.
ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, manufactures, and intends to market plasma-based biologics for the treatment and prevention of infectious diseases. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. RI-002 is an injectable immune globulin derived from human plasma enriched with high levels of naturally occurring polyclonal antibodies, as well as high levels of antibodies targeted to respiratory syncytial virus. The company also operates ADMA BioCenters, which are plasma collection centers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
Adam S Grossman’s most recent annual compensation from ADMA Biologics, Inc. is a salary of $432,692, $1,441,498 in other compensation, and a total compensation of $1,874,190. Mr. Grossman is 36 years old.
According to his biography, Mr. Adam S. Grossman is President, Chief Executive Officer, Director of ADMA Biologics, Inc. Mr. Grossman has been a director of ADMA since 2007, has served as ADMA’s President and Chief Executive Officer since October 2011 and as ADMA’s President and Chief Operating Officer between 2007 and October 2011. Mr. Grossman has over 15 years experience in the blood and plasma industry. Prior to founding ADMA, Mr. Grossman was the Executive Vice President of National Hospital Specialties and GenesisBPS, a position he held between 1994 and 2011. He has experience in launching new products, building and managing national and international sales forces, managing clinical trials, and completing numerous business development transactions. Previously, he worked at MedImmune, Inc., where he worked on marketing teams for RSV and CMV immunoglobulins, and at the American Red Cross, where he launched new products with the Biomedical Services division. Mr. Grossman received a B.S. in Business Administration, with a specialization in International Business and Marketing, from American University.
All stories in DailyStocks.com are for informational purposes only. This is NOT a stock recommendation. This DailyStocks.com story is a daily light analysis featuring a stock with insider buying. With some caveats, insiders purchase a stock because they think the stock is going up. There are other factors to consider such as size of the transaction relative to their compensation and net worth. Sometimes, insiders might be propping a stock price up for future financing. Sometimes, the amount of insider buying are misread or misreported. Each month, DailyStocks releases a a summary of the stocks with insider buying. Sign up for the free monthly newsletter at DailyStocks.com .
About Dailystocks.com: DailyStocks.com is the place where you can find stories about stocks with insider buying, where you can educate yourself about stock market investing, and where you can perform the stock search engine analysis – you enter a stock symbol, and you get a resulting page of stock ticker indexed links so that you do not have to type the stock symbol each time.